{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Allen ME"],"funding":["NHLBI NIH HHS","UNC | Nutrition Obesity Research Center, University of North Carolina","U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","Stealth BioTherapeutics","NIH HHS"],"pagination":["389"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7368046"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(1)"],"pubmed_abstract":["Mitochondrial dysfunction contributes to cardiac pathologies. Barriers to new therapies include an incomplete understanding of underlying molecular culprits and a lack of effective mitochondria-targeted medicines. Here, we test the hypothesis that the cardiolipin-binding peptide elamipretide, a clinical-stage compound under investigation for diseases of mitochondrial dysfunction, mitigates impairments in mitochondrial structure-function observed after rat cardiac ischemia-reperfusion. Respirometry with permeabilized ventricular fibers indicates that ischemia-reperfusion induced decrements in the activity of complexes I, II, and IV are alleviated with elamipretide. Serial block face scanning electron microscopy used to create 3D reconstructions of cristae ultrastructure reveals that disease"],"journal":["Communications biology"],"pubmed_title":["The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats."],"pmcid":["PMC7368046"],"funding_grant_id":["R01 HL123647","R01 HL102298","R01 HL138003","R01 HL141855","P30DK056350","1R01HL12364"],"pubmed_authors":["Poelzing S","Shaikh SR","Makrecka-Kuka M","Dambrova M","Han X","Kidd GK","Benson EK","Perry JB","Allen ME","Moukdar F","Pennington ER","Dadoo S","Brown DA","Raisch TB","Patel HD"],"additional_accession":[]},"is_claimable":false,"name":"The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats.","description":"Mitochondrial dysfunction contributes to cardiac pathologies. Barriers to new therapies include an incomplete understanding of underlying molecular culprits and a lack of effective mitochondria-targeted medicines. Here, we test the hypothesis that the cardiolipin-binding peptide elamipretide, a clinical-stage compound under investigation for diseases of mitochondrial dysfunction, mitigates impairments in mitochondrial structure-function observed after rat cardiac ischemia-reperfusion. Respirometry with permeabilized ventricular fibers indicates that ischemia-reperfusion induced decrements in the activity of complexes I, II, and IV are alleviated with elamipretide. Serial block face scanning electron microscopy used to create 3D reconstructions of cristae ultrastructure reveals that disease","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2025-04-19T18:02:40.927Z","creation":"2025-04-19T18:02:40.927Z"},"accession":"S-EPMC7368046","cross_references":{"pubmed":["32680996"],"doi":["10.1038/s42003-020-1101-3"]}}